{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:25:34Z","timestamp":1742012734655,"version":"3.38.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103570"],"award-info":[{"award-number":["82103570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13824-7","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:50:31Z","timestamp":1741971031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Zehui","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dailei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"5","key":"13824_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164(5):752\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.012.","journal-title":"Gastroenterology"},{"key":"13824_CR2","doi-asserted-by":"crossref","unstructured":"Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. BMJ. 2023;383:e073995.10.1136\/bmj-2022-073995.","DOI":"10.1136\/bmj-2022-073995"},{"key":"13824_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00856-2","author":"TF Stoop","year":"2023","unstructured":"Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, van Tienhoven G, van Santvoort HC, Molenaar IQ, Wilmink JW, Del Chiaro M, Katz MHG, Hackert T, Besselink MG, International Collaborative Group on Locally Advanced Pancreatic C. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-023-00856-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"13824_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trecan.2020.12.010","volume":"7","author":"G Panigrahi","year":"2021","unstructured":"Panigrahi G, Ambs S. How comorbidities shape Cancer biology and survival. Trends Cancer. 2021;7(6):488\u201395. https:\/\/doi.org\/10.1016\/j.trecan.2020.12.010.","journal-title":"Trends Cancer"},{"key":"13824_CR5","doi-asserted-by":"publisher","unstructured":"Collaboration NCDRF. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1.","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"13824_CR6","doi-asserted-by":"crossref","unstructured":"Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, Lang NN, Oudit GY, Touyz RM, American Heart Association Council on H, Council on, Arteriosclerosis T, Vascular B. Council on the Kidney in Cardiovascular D. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46-e57.10.1161\/HYP.0000000000000224.","DOI":"10.1161\/HYP.0000000000000224"},{"key":"13824_CR7","doi-asserted-by":"crossref","unstructured":"Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209.10.1136\/bmj.k4209.","DOI":"10.1136\/bmj.k4209"},{"issue":"2","key":"13824_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41416-022-02029-5","volume":"128","author":"Z Wu","year":"2023","unstructured":"Wu Z, Yao T, Wang Z, Liu B, Wu N, Lu M, Shen N. Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128(2):168\u201376. https:\/\/doi.org\/10.1038\/s41416-022-02029-5.","journal-title":"Br J Cancer"},{"key":"13824_CR9","doi-asserted-by":"crossref","unstructured":"Cheung KS, Chan EW, Seto WK, Wong ICK, Leung WK. ACE (Angiotensin-Converting Enzyme) Inhibitors\/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk: A Territory-Wide Study With Propensity Score Analysis. Hypertension. 2020;76(3):968\u2013\u200975.10.1161\/HYPERTENSIONAHA.120.15317.","DOI":"10.1161\/HYPERTENSIONAHA.120.15317"},{"key":"13824_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","volume":"122","author":"S Gandini","year":"2018","unstructured":"Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, Miligi L, Masala G, Caini S. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1\u20139. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.12.003.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"13824_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41416-019-0562-y","volume":"121","author":"J Kirkegard","year":"2019","unstructured":"Kirkegard J, Mortensen FV, Cronin-Fenton D. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study. Br J Cancer. 2019;121(7):622\u20134. https:\/\/doi.org\/10.1038\/s41416-019-0562-y.","journal-title":"Br J Cancer"},{"issue":"1","key":"13824_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/bjc.2016.375","volume":"116","author":"V Mandilaras","year":"2017","unstructured":"Mandilaras V, Bouganim N, Yin H, Asselah J, Azoulay L. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer. 2017;116(1):103\u20138. https:\/\/doi.org\/10.1038\/bjc.2016.375.","journal-title":"Br J Cancer"},{"key":"13824_CR13","doi-asserted-by":"crossref","unstructured":"Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23(2):221\u2013\u200930.10.1007\/s10552-011-9881-x.","DOI":"10.1007\/s10552-011-9881-x"},{"issue":"1","key":"13824_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-019-0695-y","volume":"19","author":"G Prada-Ramallal","year":"2019","unstructured":"Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19(1):53. https:\/\/doi.org\/10.1186\/s12874-019-0695-y.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"13824_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. Mendelian randomization\u2019: can genetic epidemiology contribute to Understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322. https:\/\/doi.org\/10.1093\/ije\/dyg070.","journal-title":"Int J Epidemiol"},{"issue":"15","key":"13824_CR16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.020.","journal-title":"J Am Coll Cardiol"},{"key":"13824_CR17","doi-asserted-by":"crossref","unstructured":"Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der Forouhi AD, Onland-Moret NG, van der Schouw NC, Schnabel YT, Hubacek RB, Kubinova JA, Baceviciene R, Tamosiunas M, Pajak A, Topor-Madry A, Stepaniak R, Malyutina U, Baldassarre S, Sennblad D, Tremoli B, de Faire E, Veglia U, Ford F, Jukema I, Westendorp JW, de Borst RG, de Jong GJ, Algra PA, Spiering A, van der Zee W, Klungel AH, de Boer OH, Doevendans A, Eaton PA, Robinson CB, Duggan JG, Consortium D, Consortium D, InterAct M, Kjekshus C, Downs J, Gotto JR, Keech AM, Marchioli AC, Tognoni R, Sever G, Poulter PS, Waters NR, Pedersen DD, Amarenco TR, Nakamura P, McMurray H, Lewsey JJ, Chasman JD, Ridker DI, Maggioni PM, Tavazzi AP, Ray L, Seshasai KK, Manson SR, Price JE, Whincup JF, Morris PH, Lawlor RW, Smith DA, Ben-Shlomo GD, Schreiner Y, Fornage PJ, Siscovick M, Cushman DS, Kumari M, Wareham M, Verschuren NJ, Redline WM, Patel S, Whittaker SR, Hamsten JC, Delaney A, Dale JA, Gaunt C, Wong TR, Kuh A, Hardy D, Kathiresan R, Castillo S, van der Harst BA, Brunner P, Tybjaerg-Hansen EJ, Marmot A, Krauss MG, Tsai RM, Coresh M, Hoogeveen J, Psaty RC, Lange BM, Hakonarson LA, Dudbridge H, Humphries F, Talmud SE, Kivimaki PJ, Timpson M, Langenberg NJ, Asselbergs C, Voevoda FW, Bobak M, Pikhart M, Wilson H, Reiner JG, Keating AP, Hingorani BJ, Sattar AD. N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351\u2013\u200961.10.1016\/S0140-6736(14)61183-1.","DOI":"10.1016\/S0140-6736(14)61183-1"},{"issue":"2","key":"13824_CR18","doi-asserted-by":"publisher","first-page":"e1003897","DOI":"10.1371\/journal.pmed.1003897","volume":"19","author":"J Yarmolinsky","year":"2022","unstructured":"Yarmolinsky J, D\u00edez-Obrero V, Richardson T, Pigeyre M, Sjaarda J, Par\u00e9 G, Walker V, Vincent E, Tan V, Ob\u00f3n-Santacana M, Albanes D, Hampe J, Gsur A, Hampel H, Pai R, Jenkins M, Gallinger S, Casey G, Zheng W, Amos C, Smith G, Martin R, Moreno V. Genetically proxied therapeutic Inhibition of antihypertensive drug targets and risk of common cancers: A Mendelian randomization analysis. PLoS Med. 2022;19(2):e1003897. https:\/\/doi.org\/10.1371\/journal.pmed.1003897.","journal-title":"PLoS Med"},{"key":"13824_CR19","doi-asserted-by":"crossref","unstructured":"Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F, Kutalik Z, Holmes M, Minelli C, Morrison J, Pan W, Relton C, Theodoratou E. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome open research. 2019;4:186.10.12688\/wellcomeopenres.15555.3.","DOI":"10.12688\/wellcomeopenres.15555.1"},{"key":"13824_CR20","doi-asserted-by":"publisher","first-page":"R195","DOI":"10.1093\/hmg\/ddy163","volume":"27","author":"G Hemani","year":"2018","unstructured":"Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of Pleiotropy in Mendelian randomization studies. Hum Mol Genet. 2018;27:R195\u2013208. https:\/\/doi.org\/10.1093\/hmg\/ddy163.","journal-title":"Hum Mol Genet"},{"issue":"9123","key":"13824_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(98)03228-0.","journal-title":"Lancet"},{"key":"13824_CR22","doi-asserted-by":"crossref","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.10.1016\/S1470-2045(10)70260-6.","DOI":"10.1016\/S1470-2045(10)70260-6"},{"key":"13824_CR23","unstructured":"Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis BR, Kjeldsen S, Sundstrom J, Rahimi K. Blood Pressure Lowering Treatment Trialists C. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol. 2021;22(4):558\u2013\u200970.10.1016\/S1470-2045(21)00033\u2013\u20094."},{"key":"13824_CR24","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang QL, Yuan C, Lee AA, Babic A, Ng K, Perez K, Nowak JA, Lagergren J, Stampfer MJ, Giovannucci EL, Sander C, Rosenthal MH, Kraft P, Wolpin BM. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Nat Commun. 2023;14(1):2437.10.1038\/s41467-023-38088-2.","DOI":"10.1038\/s41467-023-38088-2"},{"key":"13824_CR25","doi-asserted-by":"crossref","unstructured":"Yarmolinsky J, Diez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Pare G, Walker VM, Vincent EE, Tan VY, Obon-Santacana M, Albanes D, Hampe J, Gsur A, Hampel H, Pai RK, Jenkins M, Gallinger S, Casey G, Zheng W, Amos CI, International Lung, Cancer C, consortium, Smith P, Martin GD, Moreno RM. V. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Med. 2022;19(2):e1003897.10.1371\/journal.pmed.1003897.","DOI":"10.1371\/journal.pmed.1003897"},{"key":"13824_CR26","doi-asserted-by":"crossref","unstructured":"Valente R, Crippa S, Arnelo U, Vanella G, Zerboni G, Zarantonello L, Fogliati A, Arcidiacono PG, Vujasinovic M, Lohr JM, Falconi M, Capurso G, Del Chiaro M. The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology. 2022;22(4):516\u2013\u200924.10.1016\/j.pan.2022.03.020.","DOI":"10.1016\/j.pan.2022.03.020"},{"key":"13824_CR27","doi-asserted-by":"crossref","unstructured":"Partecke LI, Speerforck S, Kading A, Seubert F, Kuhn S, Lorenz E, Schwandke S, Sendler M, Kessler W, Trung DN, Oswald S, Weiss FU, Mayerle J, Henkel C, Menges P, Beyer K, Lerch MM, Heidecke CD, von Bernstorff W. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Pancreatology. 2016;16(3):423\u2013\u200933.10.1016\/j.pan.2016.03.005.","DOI":"10.1016\/j.pan.2016.03.005"},{"key":"13824_CR28","doi-asserted-by":"crossref","unstructured":"Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. Cancer Res. 2017;77(13):3700\u2013\u20097.10.1158\/0008-5472.CAN-17-0108.","DOI":"10.1158\/0008-5472.CAN-17-0108"},{"key":"13824_CR29","doi-asserted-by":"crossref","unstructured":"Saad A, Goldstein J, Margalit O, Shacham-Shmueli E, Lawrence YR, Yang YX, Reiss KA, Golan T, Mamtani R, Halpern N, Aderka D, Mouallem M, Goldstein A, Giantonio B, Boursi B. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29(5):599-604.10.1002\/pds.4993.","DOI":"10.1002\/pds.4993"},{"key":"13824_CR30","doi-asserted-by":"crossref","unstructured":"Weberpals J, Jansen L, van Herk-Sukel MPP, Kuiper JG, Aarts MJ, Vissers PAJ, Brenner H. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. Eur J Epidemiol. 2017;32(11):1019\u2013\u200931.10.1007\/s10654-017-0304-5.","DOI":"10.1007\/s10654-017-0304-5"},{"key":"13824_CR31","doi-asserted-by":"crossref","unstructured":"Yang Y, Wei RB, Wang ZC, Wang N, Gao YW, Li MX, Qiu Q. A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes. Diabetes Res Clin Pract. 2015;107(3):415\u2013\u200923.10.1016\/j.diabres.2014.11.007.","DOI":"10.1016\/j.diabres.2014.11.007"},{"key":"13824_CR32","doi-asserted-by":"crossref","unstructured":"Yao J, Fan S, Shi X, Gong X, Zhao J, Fan G. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials. PLoS One. 2021;16(7):e0253492.10.1371\/journal.pone.0253492.","DOI":"10.1371\/journal.pone.0253492"},{"key":"13824_CR33","doi-asserted-by":"crossref","unstructured":"Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ. Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes. 1996;45 Suppl 1:S125-8.10.2337\/diab.45.1.s125.","DOI":"10.2337\/diab.45.1.S125"},{"issue":"2","key":"13824_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0026-0495(95)90276-7","volume":"44","author":"EJ Henriksen","year":"1995","unstructured":"Henriksen EJ, Jacob S. Effects of Captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 1995;44(2):267\u2013.\u2013\u200972.10.1016\/0026\u20130495(95)90276-7.","journal-title":"Metabolism"},{"key":"13824_CR35","doi-asserted-by":"crossref","unstructured":"Chang HH, Moro A, Takakura K, Su HY, Mo A, Nakanishi M, Waldron RT, French SW, Dawson DW, Hines OJ, Li G, Go VLW, Sinnett-Smith J, Pandol SJ, Lugea A, Gukovskaya AS, Duff MO, Rosenberg DW, Rozengurt E, Eibl G. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PLoS One. 2017;12(9):e0184455.10.1371\/journal.pone.0184455.","DOI":"10.1371\/journal.pone.0184455"},{"key":"13824_CR36","doi-asserted-by":"crossref","unstructured":"Dawson DW, Hertzer K, Moro A, Donald G, Chang HH, Go VL, Pandol SJ, Lugea A, Gukovskaya AS, Li G, Hines OJ, Rozengurt E, Eibl G. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila). 2013;6(10):1064\u2013\u200973.10.1158\/1940\u20136207.CAPR-13-0065.","DOI":"10.1158\/1940-6207.CAPR-13-0065"},{"key":"13824_CR37","doi-asserted-by":"crossref","unstructured":"Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114(1):63-70.10.1080\/13813450801954451.","DOI":"10.1080\/13813450801954451"},{"key":"13824_CR38","doi-asserted-by":"crossref","unstructured":"Zhang AMY, Xia YH, Lin JSH, Chu KH, Wang WCK, Ruiter TJJ, Yang JCC, Chen N, Chhuor J, Patil S, Cen HH, Rideout EJ, Richard VR, Schaeffer DF, Zahedi RP, Borchers CH, Johnson JD, Kopp JL. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metab. 2023;35(12):2119-35 e5.10.1016\/j.cmet.2023.10.003.","DOI":"10.1016\/j.cmet.2023.10.003"},{"key":"13824_CR39","doi-asserted-by":"crossref","unstructured":"Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol. 2010;8(1):86-92.10.2174\/157016110790226642.","DOI":"10.2174\/157016110790226642"},{"key":"13824_CR40","doi-asserted-by":"crossref","unstructured":"Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D\u2019Angelo A, Maffioli P. Effects of enalapril\/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther. 2014;39(3):277\u2013\u200985.10.1111\/jcpt.12139.","DOI":"10.1111\/jcpt.12139"},{"key":"13824_CR41","doi-asserted-by":"crossref","unstructured":"Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4(5):389-401.10.1007\/s11739-009-0300-1.","DOI":"10.1007\/s11739-009-0300-1"},{"key":"13824_CR42","doi-asserted-by":"crossref","unstructured":"Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911\u2013\u200916 e12.10.1016\/j.jada.2010.03.018.","DOI":"10.1016\/j.jada.2010.03.018"},{"key":"13824_CR43","doi-asserted-by":"crossref","unstructured":"Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94(25):13915\u2013\u200920.10.1073\/pnas.94.25.13915.","DOI":"10.1073\/pnas.94.25.13915"},{"key":"13824_CR44","doi-asserted-by":"crossref","unstructured":"Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011;71(10):3582\u2013\u20099.10.1158\/0008-5472.CAN-10-2573.","DOI":"10.1158\/0008-5472.CAN-10-2573"},{"key":"13824_CR45","doi-asserted-by":"crossref","unstructured":"Kang R, Hou W, Zhang Q, Chen R, Lee YJ, Bartlett DL, Lotze MT, Tang D, Zeh HJ. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis. 2014;5(10):e1480.10.1038\/cddis.2014.445.","DOI":"10.1038\/cddis.2014.445"},{"key":"13824_CR46","doi-asserted-by":"crossref","unstructured":"Kang R, Tang D, Lotze MT, Zeh HJ 3. rd. AGER\/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy. 2012;8(6):989\u2013\u200991.10.4161\/auto.20258.","DOI":"10.4161\/auto.20258"},{"key":"13824_CR47","doi-asserted-by":"crossref","unstructured":"White DL, Hoogeveen RC, Chen L, Richardson P, Ravishankar M, Shah P, Tinker L, Rohan T, Whitsel EA, El-Serag HB, Jiao L. A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med. 2018;7(5):2180\u2013\u200991.10.1002\/cam4.1426.","DOI":"10.1002\/cam4.1426"},{"key":"13824_CR48","doi-asserted-by":"crossref","unstructured":"Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut. 2010;59(5):630\u2013\u20097.10.1136\/gut.2009.188961.","DOI":"10.1136\/gut.2009.188961"},{"key":"13824_CR49","doi-asserted-by":"crossref","unstructured":"Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, Evans DM, Smith GD. Recent Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330\u2013\u200945.10.1007\/s40471-017-0128-6.","DOI":"10.1007\/s40471-017-0128-6"},{"key":"13824_CR50","doi-asserted-by":"crossref","unstructured":"Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S, VanderWeele T, Higgins J, Timpson N, Dimou N, Langenberg C, Golub R, Loder E, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards J. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614\u2013\u200921.10.1001\/jama.2021.18236.","DOI":"10.1001\/jama.2021.18236"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13824-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:50:44Z","timestamp":1741971044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13824-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13824"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13824-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original GWASs were approved by the relevant institutional review boards and all the participants provided informed consent, therefore our study does not involve the need for approval from the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adhered to the reporting guidelines outlined in the Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) guidelines [], as presented in Table .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reporting guidelines"}}],"article-number":"476"}}